Robert J. Jones, MD, PhD, University of Glasgow & Beatson West of Scotland Cancer Centre, Glasgow, UK, discusses the final results from the cabozantinib arm of the ATLANTIS trial, which investigated cabozantinib vs. placebo in the maintenance setting for patients with advanced urothelial carcinoma. The ATLANTIS trial is a precision medicine maintenance platform trial, which enrolled patients into clinical trials based on biomarker testing of tissue collected during first-line chemotherapy. Dr Jones presented results on the cabozantinib arm, in which patients received cabozantinib or placebo as maintenance therapy until radiographic progression of disease. The trial did not report any new toxicities, but did not meet the primary endpoint of progression-free survival. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
